Currently out of the existing stock ratings of Wan Nurhayati, 5 are a HOLD (83.33%), 1 are a BUY (16.67%).
Analyst Wan Nurhayati, currently employed at CFRA, has had 66.67% of price targets met with an average potential upside of 9.29%, reached in 60 days on average.
Wan Nurhayati has documented 12 price targets and ratings displayed on 3 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on GSK, GlaxoSmithKline PLC ADR at 30-Oct-2025.
Analyst best performing recommendations are on NVS (NOVARTIS AG ADR).
The best stock recommendation documented was for NVS (NOVARTIS AG ADR) on 10/29/2025. The price target of $126 was fulfilled within 13 days with a profit of $7.8 (6.6%), with a performance score of 5.08.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 14-May-2025
$40
$2.18 (5.76%)
$47
1 months 10 days ago
(12-Oct-2026)
14/27 (51.85%)
$1.42 (3.68%)
28
Hold Since 11-Sep-2026
$40
$2.18 (5.76%)
$40
2 months 11 days ago
(11-Sep-2026)
6/6 (100%)
$-3.07 (-7.13%)
32
Buy Since 20-Nov-2025
$62
5 months 5 days ago
(17-Jun-2026)
1/2 (50%)
$15.28 (32.71%)
210
Hold Since 03-Jun-2026
$47
$9.18 (24.27%)
$41
5 months 19 days ago
(03-Jun-2026)
3/6 (50%)
$5.53 (13.33%)
41
Buy Since 12-Dec-2022
$70
$32.18 (85.09%)
$70
9 months 19 days ago
(03-Feb-2026)
2/9 (22.22%)
$22.09 (46.11%)
211
What Year was the first public recommendation made by Wan Nurhayati?